[Skip to Content]
[Skip to Content Landing]
Editorial
March 27, 2013

Is Sublingual Immunotherapy Ready for Use in the United States?

Author Affiliations

Author Affiliation: National Jewish Health, Denver, Colorado.

JAMA. 2013;309(12):1297-1298. doi:10.1001/jama.2013.2739

The administration of allergen immunotherapy by the sublingual route (sublingual immunotherapy) is increasingly used in Europe and is of increasing interest in the United States because of its convenient mode of delivery and greater safety, which allows for self-administration of treatment at home. In this issue of JAMA, Lin et al1 report results of a systematic review of sublingual immunotherapy for treatment of allergic asthma, rhinitis, and conjunctivitis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×